{"nctId":"NCT00633880","briefTitle":"Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","startDateStruct":{"date":"2008-01"},"conditions":["Symptomatic Neurogenic Orthostatic Hypotension (NOH)","Non-diabetic Neuropathy","Primary Autonomic Failure","Dopamine Beta Hydroxylase Deficiency"],"count":181,"armGroups":[{"label":"Droxidopa","type":"EXPERIMENTAL","interventionNames":["Drug: Droxidopa"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Droxidopa","otherNames":["L-DOPS","L-threo-DOPS","Northera"]}],"eligibilityModule":{"eligibilityCriteria":"PATIENT INCLUSION CRITERIA:\n\n* Male or female and aged 18 years or over;\n* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies;\n* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;\n* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.\n\nMAIN PATIENT EXCLUSION CRITERIA:\n\n* Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after a minimum 7 day washout period;\n* Taking anti-hypertensive medication;\n* Have a history of more than moderate alcohol consumption;\n* Women who are pregnant or lactating;\n* Have a history of closed angle glaucoma;\n* Have pre-existing sustained severe hypertension (BP \\> 180/110 mmHg in the sitting position);\n* Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;\n* In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness;\n* Have diabetes mellitus or insipidus;\n* Have a known or suspected malignancy;\n* Have known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;\n* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing;\n* Have a serum creatinine level \\> 130 Âµmol/L;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)","description":"OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.75"},{"groupId":"OG001","value":"1.9","spread":"3.16"}]}]}]},{"type":"SECONDARY","title":"Change in Fatigue (OHSA Item 4)","description":"OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.61"},{"groupId":"OG001","value":"1.5","spread":"2.72"}]}]}]},{"type":"SECONDARY","title":"Change in Weakness (OHSA Item 3)","description":"OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.88"},{"groupId":"OG001","value":"1.2","spread":"2.70"}]}]}]},{"type":"SECONDARY","title":"Change in Vision (OHSA Item 2)","description":"OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.79"},{"groupId":"OG001","value":"0.8","spread":"2.24"}]}]}]},{"type":"SECONDARY","title":"Change in Concentration (OHSA Item 5)","description":"OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.74"},{"groupId":"OG001","value":"0.9","spread":"2.67"}]}]}]},{"type":"POST_HOC","title":"Change in Orthostatic Hypotension Questionnaire Score (OHQ)","description":"The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.\n\nIn this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"2.176"},{"groupId":"OG001","value":"1.22","spread":"2.390"}]}]}]},{"type":"SECONDARY","title":"Change in Head/Neck Discomfort (OHSA Item 6)","description":"OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.45"},{"groupId":"OG001","value":"1.2","spread":"3.19"}]}]}]},{"type":"SECONDARY","title":"Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)","description":"The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"2.35"},{"groupId":"OG001","value":"0.91","spread":"2.50"}]}]}]},{"type":"SECONDARY","title":"Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)","description":"The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.27"},{"groupId":"OG001","value":"1.35","spread":"2.53"}]}]}]},{"type":"SECONDARY","title":"Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)","description":"OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"2.29"},{"groupId":"OG001","value":"1.07","spread":"2.25"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;","description":"Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"19.71"},{"groupId":"OG001","value":"-5.2","spread":"26.83"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Headache","Dizziness","Fall","Fatigue"]}}}